Gilead Sciences Company Profile (NASDAQ:GILD)

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences logoGilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:GILD
  • CUSIP: 37555810
  • Web: www.gilead.com
Capitalization:
  • Market Cap: $84.04 billion
  • Outstanding Shares: 1,306,728,000
Average Prices:
  • 50 Day Moving Avg: $66.50
  • 200 Day Moving Avg: $70.40
  • 52 Week Range: $63.88 - $88.85
P/E:
  • Trailing P/E Ratio: 6.80
  • Foreward P/E Ratio: 8.66
  • P/E Growth: -1.40
Sales & Book Value:
  • Annual Revenue: $29.1 billion
  • Price / Sales: 2.89
  • Book Value: $15.64 per share
  • Price / Book: 4.11
Dividend:
  • Annual Dividend: $1.88
  • Dividend Yield: 3.2%
Profitability:
  • EBIDTA: $18.24 billion
  • Net Margins: 44.43%
  • Return on Equity: 92.36%
  • Return on Assets: 29.22%
Debt:
  • Debt-to-Equity Ratio: 1.53%
  • Current Ratio: 4.17%
  • Quick Ratio: 4.00%
Misc:
  • Average Volume: 7.92 million shs.
  • Beta: 1.11
  • Short Ratio: 1.35
 

Frequently Asked Questions for Gilead Sciences (NASDAQ:GILD)

What is Gilead Sciences' stock symbol?

Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."

How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?

Gilead Sciences announced a quarterly dividend on Tuesday, May 2nd. Shareholders of record on Friday, June 16th will be paid a dividend of $0.52 per share on Thursday, June 29th. This represents a $2.08 annualized dividend and a yield of 3.23%. The ex-dividend date of this dividend is Wednesday, June 14th. View Gilead Sciences' Dividend History.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) released its quarterly earnings results on Tuesday, May, 2nd. The company reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.18 by $0.02. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.66 billion. Gilead Sciences had a net margin of 44.43% and a return on equity of 92.36%. View Gilead Sciences' Earnings History.

Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?

25 equities research analysts have issued 12-month price targets for Gilead Sciences' shares. Their forecasts range from $65.50 to $100.00. On average, they anticipate Gilead Sciences' share price to reach $81.08 in the next year. View Analyst Ratings for Gilead Sciences.

What are analysts saying about Gilead Sciences stock?

Here are some recent quotes from research analysts about Gilead Sciences stock:

  • 1. According to Zacks Investment Research, "Although Gilead’s first-quarter results beat on earnings, revenues missed expectations. The HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens which now represent 42% of total Gilead HIV prescription volume following the launch of Genvoya and the launches of Odefsey and Descovy in 2016. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales as the company saw a significant uptick in PrEP usage in 2017 with an estimated 125,000 patients using Truvada by the end of the first quarter. However, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. However, the HCV franchise continues to be under competitive and pricing pressure leading to a massive decline in Harvoni and Sovaldi sales. The company expects that the persistent decline in HCV patient starts will be the primary factor behind the year-over-year decrease." (5/5/2017)
  • 2. Maxim Group analysts commented, "Gilead reported 1Q17 results with total revenues of $6.5B, which just missed consensus expectations. Total revenues declined by 11% compared to the prior quarter’s revenues of $7.2B, and product sales were $6.4B, representing a 12% decrease sequentially. HCV product reveneues fell to $2.6B vs. $3.2B in 4Q16, down 20% as a result of declining revenues for Harvoni ($1.4B), Sovaldi ($313M), and Epclusa ($892M)." (5/3/2017)
  • 3. Jefferies Group LLC analysts commented, "U.S. sales of Harvoni are tracking in line for 1Q and Epclusa ahead of cons., which should help GILD hit numbers for now and perhaps improve sentiment. We are cautious about overinterpreting recent Rx trends given VA/pricing dynamics are not captured and many headwinds could increase over '17, and remain below cons. for out-yrs. Still, we like GILD on LT HIV sustainability and BD optionality, and believe any deal & acceptable HCV 1Q #s could improve sentiment." (3/15/2017)
  • 4. Mizuho analysts commented, "We are updating our GILD model post the company's 4Q'16 call. We maintain our Buy rating and lower our PT from $88 to $77 (vs the company's current stock price of $70) to account for the company's 4Q'16 results, 2017 guidance and comments around the HCV business." (3/1/2017)
  • 5. Needham & Company LLC analysts commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by strong Epclusa launch in HCV ($1.05B WW). HCV sales overall, however, continue to fall and mgmt issued 2017 sales guidance below expectations. We remain cautious given revenue trajectory and maintain HOLD." (2/8/2017)

Are investors shorting Gilead Sciences?

Gilead Sciences saw a drop in short interest during the month of April. As of April 28th, there was short interest totalling 10,584,715 shares, a drop of 12.2% from the April 13th total of 12,057,186 shares. Based on an average daily volume of 7,828,032 shares, the short-interest ratio is presently 1.4 days. Approximately 0.8% of the shares of the stock are sold short.

Who are some of Gilead Sciences' key competitors?

Who owns Gilead Sciences stock?

Gilead Sciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.88%), Vanguard Group Inc. (6.94%), State Street Corp (4.59%), Bank of New York Mellon Corp (2.34%), FMR LLC (1.74%) and Parnassus Investments CA (1.28%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.

Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?

Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Canada Pension Plan Investment Board, NN Investment Partners Holdings N.V., Westfield Capital Management Co. LP, Parametric Portfolio Associates LLC, Waverton Investment Management Ltd, Morgan Stanley and Pioneer Investment Management Inc.. Company insiders that have sold Gilead Sciences stock in the last year include Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter. View Insider Buying and Selling for Gilead Sciences.

Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?

Gilead Sciences' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Parnassus Investments CA, Bank of New York Mellon Corp, Renaissance Technologies LLC, Platinum Investment Management Ltd., Los Angeles Capital Management & Equity Research Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Gilead Sciences.

How do I buy Gilead Sciences stock?

Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Gilead Sciences stock cost?

One share of Gilead Sciences stock can currently be purchased for approximately $64.31.

Analyst Ratings

Consensus Ratings for Gilead Sciences (NASDAQ:GILD) (?)
Ratings Breakdown: 10 Hold Ratings, 14 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.64)
Consensus Price Target: $81.08 (26.07% upside)

Analysts' Ratings History for Gilead Sciences (NASDAQ:GILD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Credit Suisse Group AGReiterated RatingOutperform$79.00N/AView Rating Details
5/3/2017GabelliReiterated RatingBuy$85.00MediumView Rating Details
5/3/2017Barclays PLCReiterated RatingOverweight$85.00MediumView Rating Details
5/3/2017Stifel NicolausReiterated RatingBuy$87.00MediumView Rating Details
5/3/2017Robert W. BairdReiterated RatingOutperform$87.00MediumView Rating Details
5/3/2017Maxim GroupReiterated RatingHoldLowView Rating Details
5/3/2017BMO Capital MarketsReiterated RatingHold$75.00 -> $76.00LowView Rating Details
4/26/2017William BlairReiterated RatingOutperformLowView Rating Details
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
4/17/2017Cowen and CompanyReiterated RatingBuy$100.00LowView Rating Details
4/6/2017Jefferies Group LLCReiterated RatingBuy$82.00LowView Rating Details
4/6/2017JPMorgan Chase & Co.Reiterated RatingOverweight$82.00LowView Rating Details
3/13/2017Bank of America CorpReiterated RatingNeutral$76.00 -> $68.19LowView Rating Details
3/13/2017Goldman Sachs Group IncReiterated RatingNeutral$70.00 -> $68.00LowView Rating Details
3/1/2017MizuhoLower Price TargetBuy$88.00 -> $77.00N/AView Rating Details
2/14/2017Berenberg BankSet Price TargetBuy$112.00 -> $78.00N/AView Rating Details
2/8/2017Leerink SwannSet Price TargetHold$91.00 -> $74.00N/AView Rating Details
2/8/2017Royal Bank of CanadaLower Price Target$75.00N/AView Rating Details
2/8/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/8/2017Citigroup IncDowngradeBuy -> Neutral$87.00 -> $76.00N/AView Rating Details
2/8/2017Morgan StanleyLower Price TargetEqual Weight$85.00 -> $77.00N/AView Rating Details
2/8/2017Wells Fargo & CoReiterated RatingMarket Perform$79.50 -> $65.50N/AView Rating Details
10/15/2016Evercore ISISet Price TargetBuy$90.00N/AView Rating Details
7/29/2016ArgusDowngradeBuy -> Hold$88.00 -> $81.00N/AView Rating Details
7/27/2016S&P Equity ResearchReiterated RatingStrong-BuyN/AView Rating Details
5/4/2016Oppenheimer Holdings Inc.Reiterated RatingBuy$120.00 -> $116.00N/AView Rating Details
2/3/2016Standpoint ResearchInitiated CoverageBuy$110.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$111.00N/AView Rating Details
9/10/2015Jyske BankUpgradeStrong-Buy$125.00N/AView Rating Details
7/29/2015Deutsche Bank AGBoost Price Target$125.00 -> $135.00N/AView Rating Details
5/29/2015Sanford C. BernsteinReiterated RatingOutperform$125.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Gilead Sciences (NASDAQ:GILD)
Earnings by Quarter for Gilead Sciences (NASDAQ:GILD)
Earnings History by Quarter for Gilead Sciences (NASDAQ:GILD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 2017$2.18$2.20$6.66 billion$6.51 billionViewListenView Earnings Details
2/7/2017Q416$2.61$2.70$7.16 billion$7.30 billionViewListenView Earnings Details
11/1/2016Q316$2.87$2.75$7.47 billion$7.40 billionViewListenView Earnings Details
7/25/2016Q216$3.02$3.08$7.80 billion$7.78 billionViewListenView Earnings Details
4/28/2016Q116$3.13$3.03$8.08 billion$7.80 billionViewListenView Earnings Details
2/2/2016Q415$3.00$3.32$8.11 billion$8.51 billionViewListenView Earnings Details
10/27/2015Q315$2.87$3.22$7.84 billion$8.30 billionViewListenView Earnings Details
7/28/2015Q215$2.83$3.15$7.60 billion$8.22 billionViewListenView Earnings Details
4/30/2015Q115$2.78$2.94$6.81 billion$7.59 billionViewListenView Earnings Details
2/3/2015Q414$2.27$2.43$6.68 million$7.31 billionViewListenView Earnings Details
10/28/2014Q314$1.92$1.84$5.99 billion$6.04 billionViewListenView Earnings Details
7/23/2014Q214$1.61$2.36$5.68 billion$6.53 billionViewListenView Earnings Details
4/22/2014Q114$0.75$1.48$3.80 billion$5.00 billionViewListenView Earnings Details
2/4/2014Q413$0.50$0.55$2.85 billion$3.04 billionViewListenView Earnings Details
10/29/2013Q313$0.48$0.52$2.72 billion$2.78 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.50$0.50$2.66 billion$2.77 billionViewListenView Earnings Details
5/2/2013Q1 2013$0.50$0.48$2.57 billion$2.53 billionViewListenView Earnings Details
2/4/2013Q4 2012$0.48$0.50$2.43 billion$2.59 billionViewListenView Earnings Details
10/23/2012$0.94$1.00ViewN/AView Earnings Details
7/26/2012$0.95$0.99ViewN/AView Earnings Details
4/26/2012$0.94$0.91ViewN/AView Earnings Details
2/2/2012$1.04$0.97ViewN/AView Earnings Details
10/27/2011$1.01$1.02ViewN/AView Earnings Details
4/20/2011$0.97$0.87ViewN/AView Earnings Details
1/25/2011$0.95$0.95ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Gilead Sciences (NASDAQ:GILD)
2017 EPS Consensus Estimate: $8.09
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$2.09$2.42$2.23
Q2 20173$2.01$2.17$2.08
Q3 20173$1.88$2.02$1.93
Q4 20173$1.79$1.94$1.85
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Gilead Sciences (NASDAQ:GILD)
Next Dividend:6/29/2017
Annual Dividend:$1.88
Dividend Yield:2.92%
Payout Ratio:18.91% (Trailing 12 Months of Earnings)
22.90% (Based on This Year's Estimates)
25.30% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Gilead Sciences (NASDAQ:GILD)

Dividend History by Quarter for Gilead Sciences (NASDAQ:GILD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2017quarterly$0.523.09%6/14/20176/16/20176/29/2017
2/7/2017quarterly$0.523.11%3/14/20173/16/20173/30/2017
11/1/2016quarterly$0.472.59%12/13/201612/15/201612/29/2016
7/25/2016quarterly$0.472.32%9/14/20169/16/20169/29/2016
4/28/2016quarterly$0.472.13%6/14/20166/16/20166/29/2016
2/2/2016quarterly$0.431.99%3/14/20163/16/20163/30/2016
10/27/2015quarterly$0.431.59%12/14/201512/16/201512/30/2015
7/28/2015quarterly$0.431.49%9/14/20159/16/20159/29/2015
4/30/2015quarterly$0.436/12/20156/16/20156/29/2015
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Gilead Sciences (NASDAQ:GILD)
Insider Ownership Percentage: 1.40%
Institutional Ownership Percentage: 74.19%
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)
Insider Trades by Quarter for Gilead Sciences (NASDAQ:GILD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/9/2017John Francis CoganDirectorSell9,943$67.25$668,666.75View SEC Filing  
4/3/2017John C MartinInsiderSell73,333$67.18$4,926,510.94View SEC Filing  
3/30/2017Gregg H AltonEVPSell5,000$67.48$337,400.00View SEC Filing  
1/3/2017John C MartinInsiderSell73,337$73.59$5,396,869.83View SEC Filing  
11/18/2016John W MadiganDirectorSell105,000$74.86$7,860,300.00View SEC Filing  
10/3/2016John C MartinInsiderSell100,000$77.63$7,763,000.00View SEC Filing  
9/22/2016Gregg H AltonEVPSell5,000$81.84$409,200.00View SEC Filing  
9/6/2016John F MilliganInsiderSell70,000$77.74$5,441,800.00View SEC Filing  
9/1/2016John C MartinInsiderSell100,000$77.48$7,748,000.00View SEC Filing  
8/24/2016Kevin E LoftonDirectorSell3,500$81.97$286,895.00View SEC Filing  
8/1/2016John C MartinInsiderSell100,000$80.50$8,050,000.00View SEC Filing  
8/1/2016Paul Rutherford CarterEVPSell2,000$79.81$159,620.00View SEC Filing  
7/5/2016John F MilliganCEOSell112,000$84.33$9,444,960.00View SEC Filing  
7/1/2016John C MartinChairmanSell100,000$84.73$8,473,000.00View SEC Filing  
7/1/2016Paul Rutherford CarterEVPSell2,000$83.12$166,240.00View SEC Filing  
6/6/2016John F MilliganCEOSell112,000$86.94$9,737,280.00View SEC Filing  
6/1/2016Paul Rutherford CarterEVPSell2,000$87.02$174,040.00View SEC Filing  
5/2/2016John C MartinChairmanSell100,000$87.82$8,782,000.00View SEC Filing  
5/2/2016John F MilliganCEOSell112,000$87.71$9,823,520.00View SEC Filing  
5/2/2016Paul Rutherford CarterEVPSell2,000$88.72$177,440.00View SEC Filing  
4/19/2016Gregg H AltonEVPSell40,000$100.01$4,000,400.00View SEC Filing  
4/4/2016John F MilliganCEOSell112,000$94.59$10,594,080.00View SEC Filing  
4/1/2016John C MartinChairmanSell100,000$93.24$9,324,000.00View SEC Filing  
4/1/2016Paul Rutherford CarterEVPSell2,000$91.34$182,680.00View SEC Filing  
3/14/2016Gregg H AltonEVPSell5,000$90.00$450,000.00View SEC Filing  
2/26/2016Gayle E WilsonDirectorSell6,650$90.61$602,556.50View SEC Filing  
2/1/2016John C. MartinCEOSell100,000$83.42$8,342,000.00View SEC Filing  
2/1/2016Paul Rutherford CarterEVPSell2,000$82.32$164,640.00View SEC Filing  
1/4/2016John C. MartinCEOSell100,000$97.68$9,768,000.00View SEC Filing  
1/4/2016Paul Rutherford CarterEVPSell2,000$99.20$198,400.00View SEC Filing  
12/15/2015Norbert W. BischofbergerEVPSell70,000$102.41$7,168,700.00View SEC Filing  
12/7/2015John F. MilliganCOOSell100,000$103.18$10,318,000.00View SEC Filing  
11/24/2015John Francis CoganDirectorSell15,000$105.95$1,589,250.00View SEC Filing  
11/2/2015Gregg H. AltonEVPSell12,000$109.38$1,312,560.00View SEC Filing  
11/2/2015John C. MartinCEOSell150,000$109.42$16,413,000.00View SEC Filing  
11/2/2015Robin L WashingtonCFOSell6,250$109.46$684,125.00View SEC Filing  
10/27/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/26/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
10/26/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
10/15/2015Norbert W. BischofbergerEVPSell70,000$100.05$7,003,500.00View SEC Filing  
10/7/2015John F. MilliganCOOSell100,000$99.22$9,922,000.00View SEC Filing  
10/5/2015Gregg H. AltonEVPSell5,000$100.00$500,000.00View SEC Filing  
10/1/2015John C. MartinCEOSell150,000$97.48$14,622,000.00View SEC Filing  
10/1/2015Paul Rutherford CarterEVPSell2,000$98.59$197,180.00View SEC Filing  
9/15/2015Gregg H. AltonEVPSell5,000$110.00$550,000.00View SEC Filing  
9/15/2015John Francis CoganDirectorSell15,000$110.00$1,650,000.00View SEC Filing  
9/8/2015John F. MilliganCOOSell100,000$103.39$10,339,000.00View SEC Filing  
9/2/2015Robin L WashingtonCFOSell6,250$102.20$638,750.00View SEC Filing  
9/1/2015John C. MartinCEOSell150,000$102.73$15,409,500.00View SEC Filing  
8/28/2015Gayle E. WilsonDirectorSell21,000$106.96$2,246,160.00View SEC Filing  
8/25/2015John C. MartinCEOSell133,213$105.17$14,010,011.21View SEC Filing  
8/17/2015Norbert W BischofbergerEVPSell70,000$116.16$8,131,200.00View SEC Filing  
7/7/2015John F MilliganCOOSell100,000$114.44$11,444,000.00View SEC Filing  
6/26/2015John Francis CoganDirectorSell27,000$120.13$3,243,510.00View SEC Filing  
6/18/2015Paul Rutherford CarterEVPSell10,000$120.00$1,200,000.00View SEC Filing  
6/15/2015Norbert W BischofbergerEVPSell70,000$117.67$8,236,900.00View SEC Filing  
6/8/2015John F MilliganCOOSell100,000$114.05$11,405,000.00View SEC Filing  
6/1/2015Gregg H AltonEVPSell17,000$113.64$1,931,880.00View SEC Filing  
6/1/2015John C MartinCEOSell150,000$113.95$17,092,500.00View SEC Filing  
4/15/2015Norbert W BischofbergerEVPSell70,000$103.84$7,268,800.00View SEC Filing  
4/8/2015Paul Rutherford CarterEVPSell1,000$100.00$100,000.00View SEC Filing  
4/1/2015Gregg H AltonEVPSell7,000$96.53$675,710.00View SEC Filing  
4/1/2015John C MartinCEOSell150,000$96.74$14,511,000.00View SEC Filing  
3/2/2015John C MartinCEOSell150,000$103.51$15,526,500.00View SEC Filing  
3/2/2015Paul Rutherford CarterEVPSell2,000$104.18$208,360.00View SEC Filing  
3/2/2015Richard James WhitleyDirectorSell5,000$103.43$517,150.00View SEC Filing  
2/6/2015Olsen Per WoldDirectorBuy10,000$99.92$999,200.00View SEC Filing  
2/2/2015Gregg H AltonEVPSell12,000$105.73$1,268,760.00View SEC Filing  
2/2/2015John C MartinCEOSell150,000$105.43$15,814,500.00View SEC Filing  
2/2/2015Robin L WashingtonCFOSell33,192$105.38$3,497,772.96View SEC Filing  
1/15/2015Norbert W BischofbergerEVPSell70,000$98.47$6,892,900.00View SEC Filing  
1/8/2015Gregg H AltonEVPSell5,000$100.89$504,450.00View SEC Filing  
1/5/2015John C MartinCEOSell150,000$95.12$14,268,000.00View SEC Filing  
1/2/2015Gregg H AltonEVPSell7,000$95.17$666,190.00View SEC Filing  
1/2/2015Richard James WhitleyDirectorSell5,000$95.22$476,100.00View SEC Filing  
12/22/2014John Francis CoganDirectorSell26,000$95.03$2,470,780.00View SEC Filing  
12/8/2014John F MilliganCOOSell146,823$106.26$15,601,411.98View SEC Filing  
12/1/2014John C MartinCEOSell140,633$100.72$14,164,555.76View SEC Filing  
12/1/2014Paul Rutherford CarterEVPSell2,000$100.02$200,040.00View SEC Filing  
11/3/2014John C MartinCEOSell140,625$110.40$15,525,000.00View SEC Filing  
11/3/2014Richard James WhitleyDirectorSell5,000$112.02$560,100.00View SEC Filing  
11/3/2014Robin L WashingtonCFOSell33,192$110.26$3,659,749.92View SEC Filing  
10/24/2014Paul Rutherford CarterEVPSell2,000$110.00$220,000.00View SEC Filing  
10/7/2014John F MilliganCOOSell146,895$104.60$15,365,217.00View SEC Filing  
10/1/2014John C MartinCEOSell140,625$105.91$14,893,593.75View SEC Filing  
10/1/2014Paul Rutherford CarterEVPSell2,000$106.39$212,780.00View SEC Filing  
10/1/2014Richard James WhitleyDirectorSell5,000$106.99$534,950.00View SEC Filing  
9/26/2014Paul Rutherford CarterEVPSell2,000$107.47$214,940.00View SEC Filing  
9/22/2014John Francis CoganDirectorSell5,000$106.60$533,000.00View SEC Filing  
9/8/2014John F MilliganCOOSell146,895$105.99$15,569,401.05View SEC Filing  
9/2/2014Gregg H AltonEVPSell33,000$108.58$3,583,140.00View SEC Filing  
9/2/2014John C MartinCEOSell140,625$108.64$15,277,500.00View SEC Filing  
8/26/2014Paul Rutherford CarterEVPSell10,000$106.16$1,061,600.00View SEC Filing  
8/25/2014Robin L WashingtonCFOSell4,304$105.87$455,664.48View SEC Filing  
8/21/2014John Francis CoganDirectorSell5,000$101.09$505,450.00View SEC Filing  
8/14/2014Robin L WashingtonCFOSell33,556$95.56$3,206,611.36View SEC Filing  
8/1/2014Gregg H AltonEVPSell33,000$91.62$3,023,460.00View SEC Filing  
8/1/2014John C MartinCEOSell140,625$91.53$12,871,406.25View SEC Filing  
8/1/2014Richard James WhitleyDirectorSell5,000$91.00$455,000.00View SEC Filing  
8/1/2014Robin L WashingtonCFOSell30,600$91.48$2,799,288.00View SEC Filing  
7/28/2014Nicholas G MooreDirectorSell45,000$90.56$4,075,200.00View SEC Filing  
7/21/2014John Francis CoganDirectorSell5,000$89.67$448,350.00View SEC Filing  
7/8/2014Paul Rutherford CarterEVPSell16,728$86.45$1,446,135.60View SEC Filing  
7/1/2014Gregg H AltonEVPSell33,000$84.12$2,775,960.00View SEC Filing  
7/1/2014John C MartinCEOSell140,625$84.84$11,930,625.00View SEC Filing  
7/1/2014Richard James WhitleyDirectorSell5,000$83.65$418,250.00View SEC Filing  
6/30/2014Robin L WashingtonCFOSell10,400$83.98$873,392.00View SEC Filing  
6/23/2014John Francis CoganDirectorSell5,000$81.82$409,100.00View SEC Filing  
6/16/2014Norbert W BischofbergerEVPSell90,000$80.90$7,281,000.00View SEC Filing  
6/9/2014Paul Rutherford CarterEVPSell16,728$79.43$1,328,705.04View SEC Filing  
6/4/2014Robin L WashingtonCFOSell6,426$82.52$530,273.52View SEC Filing  
6/2/2014Gregg H AltonEVPSell33,000$81.35$2,684,550.00View SEC Filing  
6/2/2014Richard James WhitleyDirectorSell5,000$80.95$404,750.00View SEC Filing  
5/14/2014Norbert BischofbergerEVPSell90,000$80.65$7,258,500.00View SEC Filing  
5/6/2014Robin WashingtonCFOSell3,000$79.91$239,730.00View SEC Filing  
5/1/2014Gregg AltonEVPSell13,000$79.08$1,028,040.00View SEC Filing  
5/1/2014John MartinCEOSell140,625$79.02$11,112,187.50View SEC Filing  
5/1/2014Richard James WhitleyDirectorSell5,000$78.63$393,150.00View SEC Filing  
5/1/2014Robin WashingtonCFOSell27,600$79.16$2,184,816.00View SEC Filing  
4/14/2014Norbert BischofbergerEVPSell90,000$67.03$6,032,700.00View SEC Filing  
4/8/2014John Francis CoganDirectorSell5,000$70.55$352,750.00View SEC Filing  
4/8/2014Paul Rutherford CarterEVPSell16,728$70.53$1,179,825.84View SEC Filing  
4/1/2014Gregg AltonEVPSell13,000$73.20$951,600.00View SEC Filing  
4/1/2014John MartinCEOSell140,625$73.26$10,302,187.50View SEC Filing  
3/14/2014John Francis CoganDirectorSell14,000$76.44$1,070,160.00View SEC Filing  
3/14/2014Norbert BischofbergerEVPSell90,000$75.89$6,830,100.00View SEC Filing  
3/10/2014Paul Rutherford CarterEVPSell16,728$79.32$1,326,864.96View SEC Filing  
3/3/2014Gregg AltonEVPSell33,000$81.84$2,700,720.00View SEC Filing  
3/3/2014John MartinCEOSell140,625$81.74$11,494,687.50View SEC Filing  
2/26/2014Nicholas MooreDirectorSell20,000$84.05$1,681,000.00View SEC Filing  
2/19/2014Nicholas MooreDirectorSell19,068$83.12$1,584,932.16View SEC Filing  
1/23/2014Kevin YoungEVPSell100,000$81.44$8,144,000.00View SEC Filing  
1/21/2014Gregg AltonEVPSell120,000$80.00$9,600,000.00View SEC Filing  
1/14/2014Norbert BischofbergerEVPSell90,000$74.23$6,680,700.00View SEC Filing  
10/23/2013Kevin YoungEVPSell75,000$68.56$5,142,000.00View SEC Filing  
10/14/2013Norbert BischofbergerEVPSell90,000$62.54$5,628,600.00View SEC Filing  
9/23/2013Kevin YoungEVPSell100,000$62.88$6,288,000.00View SEC Filing  
9/16/2013Norbert BischofbergerEVPSell90,000$63.11$5,679,900.00View SEC Filing  
9/3/2013Gregg AltonEVPSell30,000$60.99$1,829,700.00View SEC Filing  
9/3/2013John MartinCEOSell282,242$60.97$17,208,294.74View SEC Filing  
8/30/2013Nicholas MooreDirectorSell151,720$60.42$9,166,922.40View SEC Filing  
8/14/2013Norbert BischofbergerEVPSell90,000$58.77$5,289,300.00View SEC Filing  
8/1/2013Gregg H AltonEVPSell30,000$61.49$1,844,700.00View SEC Filing  
8/1/2013John C MartinCEOSell282,242$61.61$17,388,929.62View SEC Filing  
7/30/2013John W MadiganDirectorSell249,000$61.97$15,430,530.00View SEC Filing  
7/15/2013Norbert W BischofbergerEVPSell90,000$57.33$5,159,700.00View SEC Filing  
7/2/2013John Francis CoganDirectorSell17,000$51.66$878,220.00View SEC Filing  
7/1/2013Gregg H AltonEVPSell30,000$52.09$1,562,700.00View SEC Filing  
7/1/2013John C MartinCEOSell282,242$52.00$14,676,584.00View SEC Filing  
7/1/2013Robin L WashingtonCFOSell45,600$52.01$2,371,656.00View SEC Filing  
6/7/2013John Francis CoganDirectorSell110,000$52.15$5,736,500.00View SEC Filing  
6/3/2013Gregg H AltonEVPSell30,000$52.77$1,583,100.00View SEC Filing  
6/3/2013John C MartinCEOSell282,242$52.84$14,913,667.28View SEC Filing  
2/28/2013Olsen Per WoldDirectorBuy10,000$43.05$430,500.00View SEC Filing  
12/3/2012Gregg H AltonEVPSell44,000$75.10$3,304,400.00View SEC Filing  
12/3/2012John C MartinCEOSell291,000$75.01$21,827,910.00View SEC Filing  
11/12/2012Robin L WashingtonCFOSell55,950$73.11$4,090,504.50View SEC Filing  
10/3/2012John F MilliganCOOSell140,000$69.85$9,779,000.00View SEC Filing  
10/2/2012Robin L WashingtonCFOSell29,500$68.62$2,024,290.00View SEC Filing  
9/4/2012Gregg H AltonEVPSell44,000$57.50$2,530,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Gilead Sciences (NASDAQ:GILD)
Latest Headlines for Gilead Sciences (NASDAQ:GILD)
Source:
DateHeadline
finance.yahoo.com logo3 Reasons Gilead Sciences, Inc. Is a Better Dividend Stock Than Amgen, Inc.
finance.yahoo.com - May 24 at 5:17 PM
finance.yahoo.com logoIs The Worst Behind Gilead Sciences?
finance.yahoo.com - May 24 at 12:00 PM
finance.yahoo.com logoValeant and Gilead: Beaten Down Bargains or Truly Terrible?
finance.yahoo.com - May 23 at 5:03 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - May 19 at 12:54 PM
nasdaq.com logoGilead Sciences Enters Oversold Territory
www.nasdaq.com - May 19 at 7:53 AM
finance.yahoo.com logoA Doomed Trump Presidency Would Be a Terrifying Development for Pharmaceutical Stocks
finance.yahoo.com - May 18 at 9:56 AM
finance.yahoo.com logo3 Dividend Stocks You Haven't Thought Of
finance.yahoo.com - May 17 at 5:24 PM
seekingalpha.com logoGilead Sciences: For The Enterprising Investor - Seeking Alpha
seekingalpha.com - May 16 at 10:24 PM
fool.com logo3 Best Dividend Stocks in Biotech
www.fool.com - May 16 at 4:14 PM
finance.yahoo.com logoBlog Coverage: Ardelyx Reports Successful Trial Results for Treatment of Patients with Irritable Bowel Syndrome with Constipation
finance.yahoo.com - May 15 at 11:20 AM
fool.com logoBetter Buy: Gilead Sciences, Inc. vs. Amgen Inc.
www.fool.com - May 14 at 9:15 AM
nasdaq.com logoWhy Gilead Sciences is the 'Top Dividend Stock of the Nasdaq 100' With 3.1% Yield (GILD)
www.nasdaq.com - May 12 at 6:04 PM
americanbankingnews.com logoShort Interest in Gilead Sciences, Inc. (GILD) Drops By 12.2%
www.americanbankingnews.com - May 12 at 7:24 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Downgraded by Vetr Inc.
www.americanbankingnews.com - May 12 at 12:40 AM
americanbankingnews.com logoJohn Francis Cogan Sells 9,943 Shares of Gilead Sciences, Inc. (GILD) Stock
www.americanbankingnews.com - May 11 at 7:41 PM
finance.yahoo.com logoMajor Biotech Short Interest Remains Mixed
finance.yahoo.com - May 10 at 11:13 AM
fool.com logoWhy Gilead Sciences Stock Lagged Behind Other Biotechs in April
www.fool.com - May 10 at 8:14 AM
finance.yahoo.com logoI Still Can't Believe Gilead Sciences, Inc. Spent $14.8 Billion on Shareholder Rewards
finance.yahoo.com - May 9 at 11:53 AM
seekingalpha.com logoGilead Vs. AbbVie: A DGI Thunderdome Match
seekingalpha.com - May 8 at 5:12 PM
finance.yahoo.com logoGilead Sciences, Inc. breached its 50 day moving average in a Bearish Manner : GILD-US : May 8, 2017
finance.yahoo.com - May 8 at 5:12 PM
americanbankingnews.com logoAnalysts Offer Predictions for Gilead Sciences, Inc.'s FY2017 Earnings (GILD)
www.americanbankingnews.com - May 8 at 10:06 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Gilead Sciences, Inc. Reduced by Analyst (GILD)
www.americanbankingnews.com - May 8 at 8:15 AM
finance.yahoo.com logoCramer's lightning round: This beaten-down biotech is a value trap
finance.yahoo.com - May 7 at 10:44 PM
americanbankingnews.com logoGilead Sciences (GILD) Receives Daily News Sentiment Rating of 0.17
www.americanbankingnews.com - May 6 at 12:53 AM
finance.yahoo.com logoCramer's lightning round: This beaten-down biotech is a value trap
finance.yahoo.com - May 5 at 10:37 PM
finance.yahoo.com logoGilead Sciences Expects Modest Revenue Performance in 2017
finance.yahoo.com - May 5 at 5:36 PM
finance.yahoo.com logoWall Street Ratings for Gilead Sciences after 1Q17 Earnings
finance.yahoo.com - May 5 at 5:36 PM
fool.com logoBetter Buy: Gilead Sciences, Inc. vs. Johnson & Johnson
www.fool.com - May 5 at 11:52 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - May 5 at 11:36 AM
finance.yahoo.com logoQuébec Demonstrates Leadership in the Treatment of HIV/AIDS by Providing Access to GENVOYA®
finance.yahoo.com - May 5 at 3:37 AM
finance.yahoo.com logoMultiple Provinces and Territories Demonstrate Leadership in the Treatment of HIV/AIDS by Providing Access to GENVOYA®
finance.yahoo.com - May 5 at 3:37 AM
finance.yahoo.com logoAnalysts On Gilead: We Think They're Mobilizing For A Deal
finance.yahoo.com - May 5 at 3:37 AM
finance.yahoo.com logoA Big, New Threat to Gilead Sciences Is Coming
finance.yahoo.com - May 4 at 5:36 PM
finance.yahoo.com logoGilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Thursday, May 18
finance.yahoo.com - May 4 at 5:36 PM
seekingalpha.com logoAssessing Gilead's Positives And Negatives - Seeking Alpha
seekingalpha.com - May 4 at 8:11 AM
finance.yahoo.com logoEdited Transcript of GILD earnings conference call or presentation 2-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 8:11 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - May 4 at 1:19 AM
americanbankingnews.com logoRobert W. Baird Reiterates "Outperform" Rating for Gilead Sciences, Inc. (GILD)
www.americanbankingnews.com - May 4 at 1:18 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Upgraded at Vetr Inc.
www.americanbankingnews.com - May 4 at 1:17 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Raised to "Strong-Buy" at Vetr Inc.
www.americanbankingnews.com - May 4 at 1:16 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Issues Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - May 4 at 12:24 AM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - May 3 at 10:28 PM
americanbankingnews.com logoGilead Sciences' (GILD) Overweight Rating Reaffirmed at Barclays PLC
www.americanbankingnews.com - May 3 at 9:54 PM
americanbankingnews.com logoGilead Sciences' (GILD) "Buy" Rating Reaffirmed at Gabelli
www.americanbankingnews.com - May 3 at 9:52 PM
247wallst.com logoGilead Faces Serious Conundrum: Value Trap vs Real Value
247wallst.com - May 3 at 7:50 PM
marketwatch.com logoGilead Sciences shares fall after earnings miss
www.marketwatch.com - May 3 at 7:50 PM
rttnews.com logoGilead Sciences Inc. (GILD) Is Falling After Q1 Miss
www.rttnews.com - May 3 at 7:50 PM
finance.yahoo.com logoGilead Sciences Posts Mixed Q1 Results: ETFs in Focus
finance.yahoo.com - May 3 at 7:50 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) to Issue Quarterly Dividend of $0.52
www.americanbankingnews.com - May 3 at 5:52 PM
americanbankingnews.com logoGilead Sciences, Inc. (GILD) Expected to Announce Quarterly Sales of $6.45 Billion
www.americanbankingnews.com - May 3 at 2:53 PM

Social

Chart

Gilead Sciences (GILD) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff